Safety and pharmacodynamic results of rontalizumab in a phase i, placebo controlled, double blind, dose escalation study in systemic lupus erythematosus
Jacqueline M. McBride PhD1,Jenny Jiang MA1, Alexander R Abbas  PhD1, Alyssa Morimoto PhD1, Jing Li PhD1,Romeo Maciuca PhD1, Michael Townsend  PhD1, Daniel J. Wallace MD FACP FACR2, William P. Kennedy MD1, Jorn Drappa MD1  DOI:10.1002/art.34632
Copyright © 2012 by the American College of Rheumatology
http://onlinelibrary.wiley.com/doi/10.1002/art.34632/abstract;jsessionid=9820893FA6E43B4D750228402B749757.d03t01
 
 
Wednesday, September 5, 2012
A new study called SKINDLE will test an  experimental skin ointment for active skin lesions caused by Discoid or Systemic Lupus Erythematosus. The drug, called R333, is a potent, topical JAK and SYK inhibitor with the potential to prevent or diminish both acute and chronic phases of this disorder. DLE is a chronic skin condition of sores with
inflammation and scarring favoring the face, ears, and scalp and at times on other body areas.
To view Rigel's animation on R333 in DLE, go to www.rigel.com/rigel/discoid_lupus.
Dr. Daniel Wallace, founder of Lupus LA and member of the S.L.E. Lupus Foundation’s Board of Directors, is conducting the study at the  Wallace Rheumatic Study Center in Los Angeles.
He can be contacted at 310-360-9197.